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PD: A neurodegenerative movement disease. 
Prevalence: Affects up to 2% of individuals over 60. 
Risk factors: Age. 
Diagnosis: Clinical & neuropsychological assessment 
Symptoms:   Motor:  tremor, slow movement, rigidity; 
                     Cognitive: impairments in multiple domains, including attention, executive,  
 function, and memory; 
                      Others:  sleep disturbance and swallowing difficulties. 
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Controls (HC)  PDN PDMCI PDD 
n  51 68 29 20 
Sex (M/F) 34/17 44/24 20/9 19/1 
Age (years) 69(8) 64(9)* 70(7) 74(7)* 
Education (years) 13(3) 13(3) 13(3) 13(2) 
Cognitive Z score 0.60(0.4) 0.24(0.4)* -0.8(0.3)* -1.7 (0.5)* 
MoCA 27.0(2.1) 26.4(2.3) 22.7(2.3)* 16.9(4.0)* 
Disease duration(years) NA 2.2(3) 4.7(6)∆ 11(8)∆ 
LED (mg/day) NA 204(298) 302(399)∆ 717(390)∆ 
Table 1.  Demographic and neuropsychological data by group 
Values are mean (sd). *p<0.001 significant ANOVA with post-hoc difference between control 
and PD subgroups & ∆p<0.001 between PDN and the other PD groups. LED = levodopa 
equivalent dose. MoCA = Montreal cognitive assessment. Cognitive Z score =  global 
cognitive ability derived from the neuropsychological battery.  
Figure 1. (A) Axial T1-wieghted image of the brain and (B) the same 










As the disease progresses, cognitive impairments become more manifest in many 
patients, ultimately leading to dementia in the majority. However, there is considerable 
variation (range 2-20 years) between onset of the initial motor disorder and the 
emergence of dementia.1 Importantly, this delay provides a window for potential 
therapeutic intervention.  
Detecting cognitive impairment at its earliest stages would facilitate the most 
appropriate and timely intervention aimed at slowing the progression to dementia. 
However, the assessment of neuroprotective and disease-modifying therapies in PD 
has been hampered by a lack of clinically useful, reliable neurobiomarkers.  
 








Cortical thickness derived from structural magnetic resonance imaging (MRI) T1-














• 168 subjects (117 PD and 51 controls) were included in this study. 
• All subjects completed a neuropsychological battery and were classified as healthy 
controls (HC), PD with normal cognition (PDN), PD with mild cognitive impairment 
(PDMCI, MDS level-II), or PD with dementia (PDD) (Table 1). 
• All subjects underwent MRI examination.  
• Three-dimensional T1-weighted (spoiled gradient echo acquisition, TE/TR=2.8/6.6ms, 
TI=400ms, voxel size=0.98×0.98×1.0mm3) images were acquired on a 3T GE HDxt 
scanner (Figure 1, A). 
• The Freesurfer was used to quantify cortical thickness (Figure 1, B). 
• We used a general linear model with age, sex and unified Parkinson's disease rating 












Cortical thickness (all groups), figure 2: 
• PDN < HC, PDN had significant cortical thinning in the left parietal and frontal 
lobes.  
• PDMCI < HC, PDMCI had significant cortical thinning bilaterally in the temporal 
and parietal lobes; and in the left frontal and occipital regions.  
• PDD < HC, PDD had significant bilateral cortical thinning in the temporal, frontal 
parietal, cingulate, occipital and insular areas.  
Cortical thickness (PD sub-groups), figure 3: 
• PDD < PDMCI, PDD had significant cortical thinning in the left frontal and 
parietal regions. 
• PDMCI < PDN, PDMCI had significant cortical thinning bilaterally in the temporal 
lobes cortices and the left parietofrontal region.  
• PDD < PDN, PDD had significant cortical thinning bilaterally in the temporal, 
frontal and parietal areas. 
Association, figure 4:  
• Cortical thinning was significantly associated with subjects’ cognitive decline 
(cognitive Z score) bilaterally in the parietal, frontal and temporal regions. 
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• In this large group of PD patients we conclude that cortical thickness measured by MRI 
may be a potential marker for cognitive impairment in PD.  
• Additional work is underway to determine whether the longitudinal rate of change of 








Figure 2. Vertex-wise cortical thinning significance maps of PDN, PDMCI and PDD 




Figure 3. Vertex-wise cortical thinning significance maps of PDMCI and PDD relative 
to PDN; and PDD relative to PDMCI. Cluster-wise correction for multiple comparisons 
(Monte-Carlo Simulation, p<0.05). 
Figure 4. Vertex-wise significance maps of the correlation between cortical thinning 
and subjects’ cognitive decline (Z score) . Cluster-wise correction for multiple 
comparisons (Monte-Carlo Simulation, p<0.05). 
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To investigate whether cortical thickness is associated with cognitive impairment in 
Parkinson's disease.  
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